Ondine completes successful SARS-CoV-2 trial
19 July 2022
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Ondine completes successful SARS-CoV-2 trial
Ondine Biomedical Inc. (AIM: OBI) announces that Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical's nasal photodisinfection technology in vaccinated COVID-19 patients with early symptoms of COVID-19.
Photodisinfection rapidly destroys pathogens including viruses, bacteria and fungi including resistant strains. This broad-spectrum approach targets the primary source of the infection as well as bacterial cofactors that may also contribute to substantial comorbidity.
Clínica Universidad de Navarra have informed the Company that top-line results from the trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in the nasal cavity of already-vaccinated individuals.
The results are being submitted for publication and the Company looks forward to updating the market at that time.
Dr. A. Fernandez-Montero, one of the three principal investigators responsible for the Clínica Universidad de Navarra clinical trial, commented:
"Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in the nasal cavity of already-vaccinated individuals. This trial confirms the early work undertaken by Canadian clinicians during the pandemic.
"We are currently in the process of submitting our results for publication and look forward to being able to discuss these and other important findings from the study in the near future."
Dr. Nicolas Loebel, President of Ondine, commented:
"The rising rates of COVID-19 due to rapidly evolving SARS-CoV-2 variants underline the importance of our broad-spectrum nasal decolonisation research. We are pleased to report that top-line results of the Clínica Universidad de Navarra clinical study in vaccinated individuals confirm findings from trials at Sunnybrook Hospital (Toronto) and Coimbra University (Portugal), as well as Canadian meat processing plant installations.
"Our goal is to be able to offer a cost-effective COVID-19 treatment and prophylaxis to help our communities deal with SARS-CoV-2 variants and other emerging threats. We are grateful to the team at the Clínica Universidad de Navarra for their expertise, facilities, and their extraordinary support in completing this important study during pandemic conditions. The study contributes to the growing body of evidence demonstrating positive outcomes with nasal photodisinfection in the prevention and treatment of COVID-19."
**ENDS**
About Ondine Biomedical Inc.
Ondine Biomedical Inc. has developed a patented, platform technology called photodisinfection which can be used in the prevention and treatment of infections, including those caused by multidrug-resistant strains and emerging bacterial, fungal and viral pathogens.
The Company has seven pipeline products under various stages of development including treatment of chronic rhinosinusitis, burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce transmission of SARS-CoV-2. Steriwave, the Company's nasal decolonisation product, has been safely and effectively used in Canadian hospitals for over ten years in the prevention of hospital-acquired infections.
For more information, please visit: www.ondinebio.com or contact:
Ondine Biomedical Inc.
Carolyn Cross, CEO +001 (1) 604 669 0555
Strand Hanson Limited (Nominated and Financial Adviser)
James Harris, James Dance +44 (0) 20 7409 3494
Arden Partners plc (Broker)
Ruari McGirr (Corporate) +44 (0) 20 7614 5900
Seb Wykeham (Sales)
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard +44 (0) 77 1000 5910
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund